In a nutshell This article looked at the outcomes of patients with extensive-stage (ES) small cell lung cancer (SCLC) treated with atezolizumab (Tecentriq), carboplatin (CP; Paraplatin), and etoposide (ET; Etopophos). The authors found that the addition of atezolizumab to CP/ET chemotherapy improved the outcomes of these...
Read More
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read More
In a nutshell This article looked at the effectiveness of exercise in improving physical and mental outcomes in patients with lung cancer undergoing chemotherapy (CT). The authors found that supervised exercise improved strength, lung function, and quality of life (QoL) in these patients. Some background Lung cancer is one of the most common...
Read More
In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...
Read More
In a nutshell This study looked at the use of chemotherapy with S-1 (Teysuno) plus cisplatin (Platinol) versus docetaxel (Taxotere) plus cisplatin and radiotherapy (RT) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. The authors found that S-1 plus cisplatin (SP) should be considered as a treatment...
Read More
In a nutshell This article looked at whether anti-cancer treatments can improve the outcomes of older patients with metastatic (cancer that has spread to a new location) non-small cell lung cancer (mNSCLC). The authors found that outcomes were improved with anti-cancer therapies in these patients. Some background NSCLC is responsible...
Read More
In a nutshell This study evaluated the impact of radiotherapy (RT) on controlling brain metastasis (BM). The study suggested that a single dose of RT was effective in controlling small BM. Larger BM could be controlled more effectively with multiple rounds of RT. Some background The spread of cancer from the original tumor to other parts of the body...
Read More
In a nutshell This article looked at the use of tumor mutation burden (TMB) to predict response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The authors found that TMB is a promising biomarker that can predict the effectiveness of ICI therapy in advanced NSCLC. Some background NSCLC...
Read More
In a nutshell This trial looked at the long-term effectiveness of gefitinib (Iressa) compared to vinorelbine (Navelbine) plus cisplatin (Platinol) for stage II-IIIA EGFR-positive non-small cell lung cancer (NSCLC). The authors found that the use of gefitinib improved disease-free survival (DFS) in these...
Read More
Barry Nelson, Patient Advisor at Brigham and Women’s Hospital Center for Patients and Families participated in a webinar on January 11 organized by The Center for Health Education Research Service in Boston, Massachusetts. [1] During the webinar, Nelson described his experience as a cancer survivor. “I was diagnosed with advanced lung cancer...
Read More
In a nutshell This article looked at the effectiveness and safety of anlotinib (AL3818) for non-responsive advanced non-small cell lung cancer (NSCLC). The authors found that anlotinib was an effective third-line or later line therapy for patients with unresponsive advanced NSCLC. Some background NSCLC accounts for 85% of lung cancers found...
Read More
In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...
Read More
